PT - JOURNAL ARTICLE AU - Fusaroli, Michele AU - Simonsen, Arndis AU - Borrie, Stephanie A. AU - Low, Daniel M. AU - Parola, Alberto AU - Raschi, Emanuel AU - Poluzzi, Elisabetta AU - Fusaroli, Riccardo TI - Identifying medications underlying communication atypicalities in psychotic and affective disorders: A pharmacovigilance study within the FDA Adverse Event Reporting System AID - 10.1101/2022.09.05.22279609 DP - 2023 Jan 01 TA - medRxiv PG - 2022.09.05.22279609 4099 - http://medrxiv.org/content/early/2023/04/17/2022.09.05.22279609.short 4100 - http://medrxiv.org/content/early/2023/04/17/2022.09.05.22279609.full AB - Purpose Communication atypicalities are considered promising markers of a broad range of clinical conditions. However, little is known about the mechanisms and confounders underlying them. Medications might have a crucial, relatively unknown role both as potential confounders and offering an insight on the mechanisms at work. The integration of regulatory documents with disproportionality analyses provides a more comprehensive picture to account for in future investigations of communication-related markers. The aim of the current study was to identify a list of drugs potentially associated with communicative atypicalities within psychotic and affective disorders.Method We developed a query using the Medical Dictionary for Regulatory Activities (MedDRA) to search for communicative atypicalities within the FDA Adverse Event Reporting System (FAERS, updated June 2021). A Bonferroni corrected disproportionality analysis (Reporting Odds Ratio) was separately performed on spontaneous reports involving psychotic, affective, and non-neuropsychiatric disorders, to account for the confounding role of different underlying conditions. Drug adverse event associations not already reported in the SIDER database of labeled adverse drug reactions (unexpected) were subjected to further robustness analyses to account for expected biases.Results A list of 291 expected and 91 unexpected potential confounding medications was identified, including drugs that may irritate (inhalants) or desiccate (anticholinergics) the larynx, impair speech motor control (antipsychotics), induce nodules (acitretin) or necrosis (VEGFR-inhibitors) on vocal cords, sedatives and stimulants, neurotoxic agents (antiinfectives), and agents acting on neurotransmitter pathways (dopamine agonists).Conclusions We provide a list of medications to account for in future studies of communication-related markers in affective and psychotic disorders. The current test case illustrates rigorous procedures for digital phenotyping, and the methodological tools implemented for large scale disproportionality analyses can be considered a roadmap for investigations of communication-related markers in other clinical populations.Competing Interest StatementRF has been a paid consultant for F. Hoffmann - La Roche.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available anonymous human data collected by the FDA and made freely available at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.htmlI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the present study are available online at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html. The data produced in the present study are available upon reasonable request to the authors.https://osf.io/e374k/